Overcoming roadblocks in the development of vaccines for leishmaniasis

PM Kaye, S Mohan, C Mantel, M Malhame… - Expert Review of …, 2021 - Taylor & Francis
Introduction The leishmaniases represent a group of parasitic diseases caused by infection
with one of several species of Leishmania parasites. Disease presentation varies because …

The delay in the licensing of protozoal vaccines: a comparative history

CB Palatnik-de-Sousa, D Nico - Frontiers in Immunology, 2020 - frontiersin.org
Although viruses and bacteria have been known as agents of diseases since 1546, 250
years went by until the first vaccines against these pathogens were developed (1796 and …

The impact of bioinformatics on vaccine design and development

RR María, CJ Arturo, JA Alicia, MG Paulina… - Vaccines, 2017 - books.google.com
Vaccines are the pharmaceutical products that offer the best cost‐benefit ratio in the pre‐-
vention or treatment of diseases. In that a vaccine is a pharmaceutical product, vaccine …

Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction against Leishmania tropica - a hierarchical subtractive proteomics and …

S Aiman, A Ahmad, AA Khan, AM Alanazi… - Frontiers in …, 2023 - frontiersin.org
Leishmania tropica is a vector-borne parasitic protozoa that is the leading cause of
leishmaniasis throughout the global tropics and subtropics. L. tropica is a multidrug-resistant …

Immunoinformatics Approach to Design a Multi-Epitope Nanovaccine against Leishmania Parasite: Elicitation of Cellular Immune Responses

M Margaroni, M Agallou, E Tsanaktsidou, O Kammona… - Vaccines, 2023 - mdpi.com
Leishmaniasis is a vector-borne disease caused by an intracellular parasite of the genus
Leishmania with different clinical manifestations that affect millions of people worldwide …

A Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes …

E Athanasiou, M Agallou, S Tastsoglou… - Frontiers in …, 2017 - frontiersin.org
Visceral leishmaniasis, caused by Leishmania (L.) donovani and L. infantum protozoan
parasites, can provoke overwhelming and protracted epidemics, with high case-fatality rates …

Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T …

MR Dikhit, A Kumar, S Das, B Dehury, AK Rout… - Frontiers in …, 2017 - frontiersin.org
Visceral leishmaniasis (VL) is one of the most neglected tropical diseases for which no
vaccine exists. In spite of extensive efforts, no successful vaccine is available against this …

Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis

B Coutinho De Oliveira, MS Duthie… - Human Vaccines & …, 2020 - Taylor & Francis
The leishmaniases are a collection of vector-borne parasitic diseases caused by a number
of different Leishmania species that are distributed worldwide. Clinical and laboratory …

Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope …

M Agallou, M Margaroni, E Athanasiou… - PLoS Neglected …, 2017 - journals.plos.org
Background Through their increased potential to be engaged and processed by dendritic
cells (DCs), nanovaccines consisting of Poly (D, L-lactic-co-glycolic acid)(PLGA) …

A chimera containing CD4+ and CD8+ T-cell epitopes of the Leishmania donovani nucleoside hydrolase (NH36) optimizes cross-protection against Leishmania …

MV Alves-Silva, D Nico, A Morrot, M Palatnik… - Frontiers in …, 2017 - frontiersin.org
The Leishmania donovani nucleoside hydrolase (NH36) and NH A34480 of Leishmania
amazonensis share 93% of sequence identity. In mice, the NH36 induced protection against …